Meeting
2023 ASCO Annual Meeting
Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.
Authors
Olatunji B. Alese
Winship Cancer Institute of Emory University, Atlanta, GA
Olatunji B. Alese , Maria Diab , Olumide B. Gbolahan , Ashley McCook-Veal , Walid Labib Shaib , Christina Wu , Mehmet Akce , Yuan Liu , Gregory B. Lesinski , Bassel F. El-Rayes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03983993
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3579)
DOI
10.1200/JCO.2023.41.16_suppl.3579
Abstract #
3579
Poster Bd #
279
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
A phase II study of niraparib in combination with EGFR inhibitor panitumumab in patients with advanced colorectal cancer.
First Author: Olatunji B. Alese
Poster
2016 ASCO Annual Meeting
Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).
First Author: Josep Tabernero
Poster
2022 ASCO Annual Meeting
Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer.
First Author: Christine Megerdichian Parseghian
Poster
2021 ASCO Annual Meeting
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
First Author: Kensei Yamaguchi